Conceivable Life Sciences announced its $50 million Series A financing to accelerate the development and commercialization of the world's first AI-powered automated IVF laboratory. The funding will support the company's mission to make this Nobel Prize-winning therapy more accessible, scalable, and effective at delivering improved pregnancy results.

The Series A round was led by Advance Venture Partners (AVP) with participation from existing investors including ARTIS Ventures, Stride, and ACME. This round brings Conceivable's total funding to $70 million, including the company's $20 million seed round, which closed in December 2022.